溃疡性结肠炎的方方面面.pptxVIP

溃疡性结肠炎;Introduction ;Introduction ;Consensus;Management consensus of inflammatory bowel disease forthe Asia–Pacific region 2006;The Asia-Pacific consensus on ulcerative colitis 2010;European evidence-based consensus on the diagnosis/management of ulcerative colitis 2008;2nd European evidence-based consensus on the diagnosis/management of ulcerative colitis 2012;Background;第九届中华消化病学分会炎症性肠病学组成员名单 ;Ulcerative colitis in China: Retrospective analysis of 3100hospitalized patients;Epidemiolgy;Etiology and Pathogenesis;菌群失调;Family history;Risk factors;Protective factors;Clinical Presentation;肠外表现(Extraintestinal manifestations);并发症(Complications);Serological markers;Serum proteins;尿白蛋白;巨细胞病毒(CMV);难辨梭状芽孢杆菌 （Clostridium difficile ）;Fecal markers;Fecal markers;Fecal markers;钡剂灌肠;CT;结肠镜检查;Typical endoscopic findings;放大内镜 (Confocal microscopy);small-bowel capsule endoscopy (SBCE).;SBCE;黏膜活检组织学检查;Microscopic findings in biopsies;诊断要点;Diagnostic criteria;鉴别诊断;Differentiate diagnosis;Differentiate diagnosis;International Study Group for Behcet’s disease. Criteria for thediagnosis of Behcet’s disease. Lancet 1990;335:1078–1080.;Evaluation and assessment;Clinical Subtype;Truelove and Witts Severity Index;Montreal classification According to Disease Extent;Montreal classification According to Disease Severity;Sutherland Index （DAI）;Mayo Score;Sutherland Index (also called Mayo scores);Endoscopic scores;Baron endoscopic scores;Endoscopic scores (UCEIS );Histologic findings;UCDAI;Different grades used for evaluation of disease severity in UC histologically;诊断与治疗;Treatment goals;SASP;氨基水杨酸制剂;GCs;6MP/AZA;Indications and Contraindications for Infliximab Therapy in IBD;Other biotechnology agents;Infliximab;Diet and nutrition;Diet and nutrition;Diet, nutrition and probiotics;Antibiotics;其他;禁忌;Rescue Therapy;CsA;Infliximab;Infliximab;Tacrolimus (FK506);Ogata H, Matsui T, Nakamura M et al. A randomized dose finding study of oral tacrolimus (FK506) therapy